Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MLYCD | O95822 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.57 |
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.57 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.57 |
| ▸ | NAMPT | P43490 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | ACLY | P53396 | 1/20 | 0.46 |
| ▸ | ACACB | O00763 | 1/20 | 0.44 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.44 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.44 |
| ▸ | AURKA | O14965 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8590217 | 0.87 | MLYCD (0.70) | MLYCDALDH1A1LMNAALOX15CYP1A2 | |
| SCHEMBL18893317 | 0.84 | MLYCD (0.58) | MLYCDALDH1A1LMNAALOX15CYP1A2 | |
| SCHEMBL3440304 | 0.83 | MLYCD (0.61) | MLYCDALDH1A1LMNAALOX15CYP1A2 | |
| SCHEMBL19345656 | 0.83 | CA2 (0.59) | ALDH1A1LMNAALOX15CYP1A2CYP2C19 | |
| SCHEMBL10052242 | 0.81 | MLYCD (0.63) | MLYCDALDH1A1LMNAALOX15CYP1A2 | |
| SCHEMBL5502887 | 0.81 | CACNA1B (0.61) | MLYCDALDH1A1LMNAALOX15CYP1A2 | |
| SCHEMBL20086461 | 0.79 | ALDH1A1 (0.60) | MLYCDALDH1A1LMNANAMPTMAPT | |
| SCHEMBL10294732 | 0.79 | MLYCD (0.53) | MLYCDALDH1A1LMNAALOX15CYP1A2 | |
| SCHEMBL10294128 | 0.79 | MLYCD (0.57) | MLYCDALDH1A1LMNAALOX15CYP1A2 | |
| SCHEMBL13761387 | 0.79 | MLYCD (0.61) | MLYCDALDH1A1LMNAALOX15CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210292285-A1 | HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS | NUVATION BIO INC (US) | 2021-09-23 | — | — | US | disclosed |
| US-11028058-B2 | Heterocyclic compounds as adenosine antagonists | NUVATION BIO INC. (US) | 2021-06-08 | — | — | US | disclosed |
| US-20190023666-A1 | HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS | SAGARD HOLDINGS MANAGER LP, AS ADMINISTRATIVE AGENT (CA) | 2019-01-24 | — | — | US | disclosed |
| US-7576117-B1 | Cyclic amine CCR3 antagonist | TEIJIN LIMITED (JP) | 2009-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190023666-A1 | HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS | ADORA2A, ADORA3, ADORA1 | MLYCD 2744/4885ALDH1A1 2100/4885LMNA 4458/4885 |
| US-11028058-B2 | Heterocyclic compounds as adenosine antagonists | ADORA2A, ADORA3, ADORA1 | MLYCD 2744/4885ALDH1A1 2100/4885LMNA 4458/4885 |
| US-20210292285-A1 | HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS | ADORA2A, ADORA3, ADORA1 | MLYCD 2744/4885ALDH1A1 2100/4885LMNA 4458/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.